All Metrics: The State of Metabolic Health in America, 2026
This page lists all 100 metrics in the 2026 Baseline Edition, organized by series. Each metric has a stable ID that will not be reused or renumbered in future editions. Metric IDs use the format: series code followed by a two-digit number (for example, MH-01).
How Metric IDs Work
Each metric ID consists of the two-letter series code and a sequential number: for example, MH-01 is the first metric in the America's Metabolic Health series. IDs are assigned once and will not be reused or renumbered in future editions, so citations remain stable across years. New metrics added in future editions receive new IDs; retired metrics are noted in the update log.
America's Metabolic Health (MH)
| Metric ID | Metric | Value | Year | Source |
|---|---|---|---|---|
| MH-01 | Adult obesity prevalence | 40.3% | 2023 | CDC, National Center for Health Statistics (NCHS) |
| MH-02 | Severe obesity prevalence (BMI ≥ 40) | 9.7% | 2017–2020 | CDC, NHANES |
| MH-03 | Adults with diagnosed or undiagnosed diabetes | More than 40 million | 2024 | CDC, National Diabetes Statistics Report |
| MH-04 | Adults with prediabetes | More than 115 million | 2024 | CDC, National Diabetes Statistics Report |
| MH-05 | Adult hypertension prevalence (measured) | 47.7% | 2023 | CDC, NHANES |
| MH-06 | Adults with chronic kidney disease unaware of diagnosis | ~90% | 2024 | National Kidney Foundation / CDC |
| MH-07 | Metabolic syndrome prevalence | 38.5% | 2023 | CDC, NHANES |
| MH-08 | Adults with diabetes who also have CKD | ~38% | 2026 | CDC, March 2026 estimates |
| MH-09 | Adults with hypertension who also have CKD | ~21% | 2026 | CDC, March 2026 estimates |
| MH-10 | Adults with prediabetes who also have CKD | ~11% | 2026 | CDC, March 2026 estimates |
Economic Impact (EI)
| Metric ID | Metric | Value | Year | Source |
|---|---|---|---|---|
| EI-01 | U.S. national health expenditures | $5.3 trillion | 2024 | CMS, National Health Expenditure Accounts |
| EI-02 | Total economic cost of diagnosed diabetes | $412.9 billion | 2022 | American Diabetes Association |
| EI-03 | Direct medical costs of diagnosed diabetes | $306.6 billion | 2022 | American Diabetes Association |
| EI-04 | Indirect costs of diagnosed diabetes (lost productivity) | $106.3 billion | 2022 | American Diabetes Association |
| EI-05 | Annual illness-related lost productivity for U.S. employers | $575 billion | 2024 | Integrated Benefits Institute |
| EI-06 | Diabetes- and hypertension-related mortality, rural adults | 85.6 | 2020 | CDC |
| EI-07 | Diabetes- and hypertension-related mortality, urban adults | 71.7 | 2020 | CDC |
| EI-08 | Adult obesity prevalence, Black adults | 49.9% | 2024 | CDC, BRFSS |
| EI-09 | Adult obesity prevalence, Hispanic adults | 45.6% | 2024 | CDC, BRFSS |
| EI-10 | Adult obesity prevalence, white adults | 41.4% | 2024 | CDC, BRFSS |
Employer Healthcare (EH)
| Metric ID | Metric | Value | Year | Source |
|---|---|---|---|---|
| EH-01 | Average employer-sponsored family health insurance premium | $26,993 | 2025 | KFF Employer Health Benefits Survey 2025 |
| EH-02 | Average worker contribution toward family coverage | $6,850 | 2025 | KFF Employer Health Benefits Survey 2025 |
| EH-03 | Average worker contribution toward single coverage | $1,440 | 2025 | KFF Employer Health Benefits Survey 2025 |
| EH-04 | Average employer health benefit cost per employee | $17,496 | 2025 | Mercer National Survey of Employer-Sponsored Health Plans 2025 |
| EH-05 | Projected employer health benefit cost increase | 6.7% | 2026 projection | Mercer National Survey of Employer-Sponsored Health Plans 2025 |
| EH-06 | Prescription drug spending increase, large employers | 9.4% | 2025 | Mercer National Survey of Employer-Sponsored Health Plans 2025 |
| EH-07 | Workers at large firms enrolled in self-funded plans | 80% | 2025 | KFF Employer Health Benefits Survey 2025 |
| EH-08 | Mid-size employers covering GLP-1s for weight loss | 19% | 2025 | KFF Employer Health Benefits Survey 2025 |
| EH-09 | Large employers covering GLP-1s for weight loss | 43% | 2025 | KFF Employer Health Benefits Survey 2025 |
| EH-10 | Large employers requiring lifestyle program for GLP-1 coverage | 34% | 2025 | KFF Employer Health Benefits Survey 2025 |
Medicare (MA)
Medicaid (MD)
Public Health Infrastructure and Prevention (PH)
| Metric ID | Metric | Value | Year | Source |
|---|---|---|---|---|
| PH-01 | Adult obesity prevalence, Colorado (lowest state) | 25.0% | 2024 | CDC, BRFSS 2024 |
| PH-02 | Adult obesity prevalence, West Virginia (highest state) | 41.4% | 2024 | CDC, BRFSS 2024 |
| PH-03 | Adult obesity prevalence, Mississippi | 40.4% | 2024 | CDC, BRFSS 2024 |
| PH-04 | Adult obesity prevalence, Louisiana | 39.2% | 2024 | CDC, BRFSS 2024 |
| PH-05 | Adult obesity prevalence, Midwest region | 35.9% | 2024 | CDC, BRFSS 2024 |
| PH-06 | Adult obesity prevalence, South region | 34.5% | 2024 | CDC, BRFSS 2024 |
| PH-07 | Adult obesity prevalence, West region | 30.2% | 2024 | CDC, BRFSS 2024 |
| PH-08 | Adult obesity prevalence, Northeast region | 30.3% | 2024 | CDC, BRFSS 2024 |
| PH-09 | Diagnosed diabetes prevalence, rural adults | 12.3% | 2024 | CDC, National Health Interview Survey (NHIS) |
| PH-10 | Diagnosed diabetes prevalence, urban adults | 9.3% | 2024 | CDC, National Health Interview Survey (NHIS) |
State-by-State Variation (SV)
| Metric ID | Metric | Value | Year | Source |
|---|---|---|---|---|
| SV-01 | Self-reported hypertension prevalence, Colorado (lowest state) | 24.6% | 2021 | CDC, BRFSS 2021 |
| SV-02 | Self-reported hypertension prevalence, Mississippi (highest state) | 40.6% | 2021 | CDC, BRFSS 2021 |
| SV-03 | National self-reported hypertension prevalence (age-standardized) | 30.1% | 2021 | CDC, BRFSS 2021 |
| SV-04 | Rural diagnosed diabetes prevalence, Colorado (lowest state) | 8.4% | 2021 | CDC, BRFSS 2021 |
| SV-05 | Rural diagnosed diabetes prevalence, North Carolina (highest state) | 21.3% | 2021 | CDC, BRFSS 2021 |
| SV-06 | Urban diagnosed diabetes prevalence, Colorado (lowest state) | 6.9% | 2021 | CDC, BRFSS 2021 |
| SV-07 | Urban diagnosed diabetes prevalence, West Virginia (highest state) | 15.5% | 2021 | CDC, BRFSS 2021 |
| SV-08 | Adult obesity prevalence, Asian adults | 16.1% | 2024 | CDC, BRFSS 2024 |
| SV-09 | States where every adult has obesity prevalence of at least 25% | 50 of 50 | 2024 | CDC, BRFSS 2024 |
| SV-10 | South census region diabetes/hypertension mortality rank | Highest | 2020 | CDC |
Medicaid Innovation (MI)
| Metric ID | Metric | Value | Year | Source |
|---|---|---|---|---|
| MI-01 | NC Healthy Opportunities Pilots: emergency department visit reduction | Statistically significant reduction | 2026 | UNC Cecil G. Sheps Center, June 2026 summative evaluation |
| MI-02 | NC Healthy Opportunities Pilots: effect on hemoglobin A1c | No statistically significant effect | 2026 | UNC Cecil G. Sheps Center, June 2026 summative evaluation |
| MI-03 | NC Healthy Opportunities Pilots: effect on blood pressure | No statistically significant effect | 2026 | UNC Cecil G. Sheps Center, June 2026 summative evaluation |
| MI-04 | NC Healthy Opportunities Pilots: Section 1115 waiver authorization year | 2019 | 2019 | CMS Section 1115 waiver records |
| MI-05 | States with Medicaid Section 1115 waivers for health-related social needs | 25 | 2026 | CMS Section 1115 waiver approvals |
| MI-06 | Medicaid GLP-1 obesity coverage: states that eliminated benefit (Oct 2025–Jan 2026) | 4 | October 2025–January 2026 | KFF Medicaid coverage tracker |
| MI-07 | Medicaid cardiometabolic multimorbidity burden (2+ conditions) | 29.7% | 2024 | KFF analysis of Medicaid data |
| MI-08 | Medicaid enrollment decline (March 2025 to March 2026) | 4.3 million | March 2025–March 2026 | CMS Medicaid enrollment data |
| MI-09 | NC Healthy Opportunities Pilots: hospital stay reduction | Statistically significant reduction | 2026 | UNC Cecil G. Sheps Center, June 2026 summative evaluation |
| MI-10 | NC Healthy Opportunities Pilots: shift to lower-cost settings | More visits to outpatient and primary care | 2026 | UNC Cecil G. Sheps Center, June 2026 summative evaluation |